Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: Anne Stehley who wrote (482)	12/30/1997 10:25:00 AM
From: Ie Coan Bie	Read Replies (1) \| Respond to of 1837

Good News is coming out: FDA Authorizes Duramed Pharmaceuticals, Inc. to Market Estradiol Tablets newsalert.com Abi

To: Anne Stehley who wrote (482)	12/30/1997 10:28:00 AM
From: KS	Read Replies (2) \| Respond to of 1837

To All: CINCINNATI, Dec. 30 /PRNewswire/ -- The U.S. Food and Drug Administration(FDA) has authorized Duramed Pharmaceuticals, Inc. (Nasdaq: DRMD) to market Estradiol Tablets, a women's hormone replacement therapy, in the 0.5 mg, 1 mg,and 2 mg strengths. The FDA granted Duramed's Estradiol Tablets a therapeutic equivalency rating of AB, designating Duramed's Estradiol Tablets as completely interchangeable with Estrace Tablets, for all new and refill prescriptions. In addition, the FDA granted Duramed the rights to market a 1.5 mg Estradiol Tablet, a strength which is presently unavailable from any other source. Annual manufacturers' revenue for the product in 1996 was approximately $100 million. Mr. E. Thomas Arington, Chairman and CEO of Duramed said, "FDA approval of this product is significant because Estradiol is the first product in our family of female hormonal products to be approved. The product will be manufactured in Duramed's state-of-the-art hormonal products facility in Cincinnati and shipment is scheduled to commence in January 1998." Mr. Arington further stated, "As we move into 1998, we look forward to new product filings as well as FDA approvals throughout the year as the depth of our product development program becomes evident." Regarding the company's synthetic conjugated estrogens product, Mr. Arington commented, "Consistent with our earlier updates, Duramed is finalizing the clinical work and anticipates filing the NDA for this product during the first quarter of 1998." Duramed Pharmaceuticals, Inc. manufactures and markets a line of prescription generic drug products in tablet, capsule, and liquid forms. * Estrace(R) is a registered trademark of Bristol Myers Squibb. SOURCE Duramed Pharmaceuticals, Inc. CONTACT: Investor Relations of Duramed Pharmaceuticals, 513-731-9900; or Media, Ellen Knight or Julie Harrison of Dan Pinger Public Relations, 513-564-0700